Search Results
EPIC update: observational study of first-line acalabrutinib treatment for CLL
The current role of acalabrutinib in the treatment of CLL
Selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in CLL
Acalabrutinib vs ibrutinib in R/R CLL: assessing the burden of adverse events
The value of BTK inhibitors in CLL & the future of acalabrutinib in this disease
The value of zanubrutinib in the CLL treatment armamentarium & SEQUOIA trial updates
Acalabrutinib: A Deep Dive into its Mechanism of Action, Applications, and Potential Side Effects
Observational Study
Impacts of the MURANO study for future CLL treatment
Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series
EPIC: estudio observacional del tratamiento de primera línea con acalabrutinib para la LLC
October 7, 2020 MassCPR Global Perspectives on COVID-19
